Shares of The Spectranetics Corp. (NASDAQ:SPNC) have been assigned a consensus rating of “Buy” from the fourteen brokerages that are covering the stock. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $25.50.

A number of research firms have weighed in on SPNC. Canaccord Genuity restated a “buy” rating and set a $30.00 price target on shares of The Spectranetics Corp. in a research report on Friday, July 29th. Needham & Company LLC reiterated a “buy” rating and issued a $32.00 price objective on shares of The Spectranetics Corp. in a report on Friday, October 28th. TheStreet upgraded The Spectranetics Corp. from a “sell” rating to a “hold” rating in a report on Monday, August 1st. RBC Capital Markets reiterated a “sector perform” rating and issued a $24.00 price objective (up previously from $17.00) on shares of The Spectranetics Corp. in a report on Monday, August 1st. Finally, Royal Bank Of Canada lifted their price objective on The Spectranetics Corp. from $17.00 to $24.00 and gave the stock a “sector perform” rating in a report on Monday, August 1st.

Shares of The Spectranetics Corp. (NASDAQ:SPNC) opened at 23.45 on Tuesday. The company’s market cap is $1.01 billion. The company’s 50 day moving average price is $23.49 and its 200 day moving average price is $21.56. The Spectranetics Corp. has a 12 month low of $11.09 and a 12 month high of $25.81.

The Spectranetics Corp. (NASDAQ:SPNC) last released its quarterly earnings results on Thursday, October 27th. The company reported ($0.22) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.05. The Spectranetics Corp. had a negative return on equity of 43.16% and a negative net margin of 21.19%. The business had revenue of $68.27 million for the quarter, compared to the consensus estimate of $17.36 million. During the same quarter last year, the business posted ($0.17) earnings per share. The company’s revenue for the quarter was up 10.7% on a year-over-year basis. On average, equities analysts expect that The Spectranetics Corp. will post ($1.08) EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of SPNC. Teacher Retirement System of Texas boosted its stake in The Spectranetics Corp. by 13.7% in the second quarter. Teacher Retirement System of Texas now owns 5,974 shares of the company’s stock valued at $112,000 after buying an additional 720 shares during the last quarter. SECOR Capital Advisors LP purchased a new stake in The Spectranetics Corp. during the second quarter valued at $376,000. Nationwide Fund Advisors boosted its stake in The Spectranetics Corp. by 2.6% in the second quarter. Nationwide Fund Advisors now owns 42,634 shares of the company’s stock valued at $798,000 after buying an additional 1,086 shares during the last quarter. Accredited Investors Inc. boosted its stake in The Spectranetics Corp. by 0.7% in the second quarter. Accredited Investors Inc. now owns 40,279 shares of the company’s stock valued at $754,000 after buying an additional 279 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its stake in The Spectranetics Corp. by 0.3% in the second quarter. PNC Financial Services Group Inc. now owns 155,442 shares of the company’s stock valued at $2,908,000 after buying an additional 515 shares during the last quarter. 97.55% of the stock is currently owned by institutional investors and hedge funds.

The Spectranetics Corp. Company Profile

The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are used to cross, prepare and treat arterial blockages in the heart and legs and to manage pacemaker and defibrillator cardiac leads.

5 Day Chart for NASDAQ:SPNC

Receive News & Stock Ratings for The Spectranetics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Spectranetics Corp. and related stocks with our FREE daily email newsletter.